Post-COVID-19: The Next Normal in Clinical Research Date Published: Sep 01, 2020 Article With the recent rise of virtual and digital methodologies during the global pandemic, experts discuss what the industry can expect for future clinical trial research. As the industry rapidly works to develop vaccines against SARS-CoV-2, more pharmaceutical companies are collaborating and looking for innovative ways to improve clinical trials for the future. A discussion among industry experts, this article explores how leveraging technology, real-time data, and analytics can improve current processes. With the pandemic-related adoption of decentralized clinical trials, technology’s role within clinical trials is expected to grow. Read these experts’ predictions on what sponsors and sites will need to do to meet the everchanging clinical trial needs. Read More Share: LinkedInTweet Recommended Resources Article #NoGoingBack: Make the Pledge In this Pharmaceutical Outsourcing feature, Signant Health's Chief Marketing Officer Scott Connor argues why the industry can’t afford to lose the progress made during COVID-19. He details why the #NoGoingBack industry-wide social movement matters. Chaired by industry members across organizations, #NoGoingBack has shown that competitors can and should collaborate to help protect research and allow it to reach new levels. Read more on how the adoption of technology benefits the greater research, not just COVID-19 vaccines. Interested in joining the movement? Pledge your name by visiting: www.nogoingback.health. Download Now Biotech Better: Solutions for Emerging Biotech/Biopharma Trials Download Now Brochure Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now